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Abstract
Objective: To describe and compare changes in participation over a 9-year period in women and men with myotonic dystrophy type 1 (DM1). To
compare participation restrictions with available reference values from a typical aging population living in the community.
Design: Descriptive longitudinal design comparing data from baseline (2002) with data from follow-up (2011).
Setting: Neuromuscular clinic and participant’s home.
Participants: Adults with DM1 participated in the follow-up study (NZ115).
Interventions: Not applicable.
Main Outcome Measure: The Assessment of Life Habits measured participation in 10 domains of daily and social activities. The minimal
clinically important difference is 0.5 on a 10-point scale for participation accomplishment level.
Results: A total of 62% of participants were women, and the mean age was 52.310.3 years. A decline (P<.01) was observed with increasing
difficulty and assistance required in global participation (mean  SD, 0.50.9), social activities subscore (0.61.2), nutrition (0.71.4),
fitness (1.01.6), personal care (0.71.2), mobility (0.51.9), community life (0.81.9), and recreation (1.53.0). More life areas
are disrupted over time: 8 domains were below reference values from a population aged 55-64 years at follow-up compared with 2 domains
at baseline. Satisfaction with participation remains high and stable over time.
Conclusion: As disease duration increases, global participation and more daily and social domains were restricted with increasing difficulty and
assistance required. Adults with DM1 showed not only age-associated but disease-specific changes in participation. Description over time of
participation could improve clinical assessment and guide interdisciplinary management of DM1, leading to higher rehabilitation success. Further
investigation of the factors influencing changes in participation is required to support disease management and services planning.
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1630 K. Raymond et alMyotonic dystrophy type 1 (DM1) is the most prevalent neuro-
muscular disorder in adults.1 DM1 is a dominant hereditary
multisystemic disease with high heterogeneity in the clinical
picture.2 The large variability within and between individuals in
terms of signs and symptoms has led to a classification into 4 or 5
phenotypes: congenital, childhood, juvenile (or early adult), adult,
and late-onset.3-5 This disease is usually characterized by pro-
gressive muscle weakness, myotonia, fatigue, dysphagia, cognitive
impairment, and a plethora of other potential signs and symp-
toms.2 The pattern of involvement and progression of the disease
has led several teams to compare DM1 with a premature aging
population.6-8 Furthermore, quality of life9,10 and participation11
are often jeopardized for people with DM1. As a measure of
rehabilitation success,12-14 participation can be defined with the
Human Development ModeleDisability Creation Process (HDM-
DCP) framework as the accomplishment of daily activities and
social roles resulting from the interaction of personal and envi-
ronmental factors.15 Because social roles are not defined in the
typical sense (eg, role of father) but with observable activities,16
the term social activities is used in this article.
Participation restrictions in daily and social activities secondary to
DM1 may have significant individual, societal, and financial conse-
quences. For instance, quality of life has been associated with
participation.17 Medical, nonmedical, and indirect costs of $32,236
per year were estimated in the United States.18 Because no cure is
available yet, long-term interdisciplinary care is required to optimize
participation.19 Indeed, participation restrictions in DM1 could be
prevented or diminished by health care and community services.20
Long-term management may include maintaining physical capacity
with exercise programs21,22 or environmental adaptations.23
One cross-sectional study found that individuals with the adult
and late-onset phenotypes experience participation restrictions
mainly in employment, housing (ie, home maintenance), mobility,
and recreation.11 Similar results were found for activities related to
housing, community life, and recreation.24 As the disease progresses,
individuals with DM1 and their close relatives modify their activ-
ities,25 usually giving up physically demanding ones26 and per-
forming others partially.27 Additionally, longitudinal studies found a
decline in the performance of activities related to personal care,
housing, mobility, and recreation.9,28 Although this is important in-
formation for the long-termmanagement of the disease, no study has
considered changes in communication, responsibilities, interpersonal
relationships, and community life. Considering the slow progres-
sion,29 it makes sense to examine participation over a lengthier time
period.30 Moreover, although DM1 is distributed equally between
women and men,2 a sex difference is shown for the presence of
multiple symptoms31 and for progressivemuscleweakness.29,32,33 To
our knowledge, no research has studied long-term participation
changes or considered sex difference over time for individuals
with DM1.List of abbreviations:
CTG cytosine-thymine-guanine
DM1 myotonic dystrophy type 1
HDM-DCP Human Development ModeleDisability Cre-
ation Process
ICC intraclass correlation coefficient
LIFE-H Assessment of Life Habits
MCID minimal clinically important difference
MIRS Muscular Impairment Rating Scale
RM-ANOVA repeated measures analysis of varianceThus, this study aimed to describe changes in participation
over a 9-year period in adults with DM1 and to explore sex
discrepancy. As an exploratory objective, this study also compared
participation in adults with DM1 with available reference values
from a typical aging population as an alternative to compare with a
general population control group. Three hypotheses were formu-
lated, namely, participation restrictions in individuals with DM1
should (1) increase over time, (2) be different according to sex,
and (3) be greater than the typical aging population.Methods
Design and participants
This descriptive longitudinal study compared baseline (2002-2004)
and follow-up (2011-2013) assessments of adults with DM1
registered at a neuromuscular clinic. At baseline, 200 adults took
part in the study, and recruitment has been described elsewhere.11,34
French-speaking individuals 18 years or older with the adult
(including juvenile) or late-onset phenotypes confirmed by genetic
analysis were included. Congenital and childhood phenotypes were
excluded because they presented with earlier onset, more severe
impairment,35 and different prognoses.36 Participants had late-onset
if they presented with at least 2 of the following: (1)<200 cytosine-
thymine-guanine (CTG) repeats, 2) a Muscular Impairment Rating
Scale (MIRS) score of 1 (no muscular impairment) or 2 (minimal
signs), or (3) the patient’s report of frequent symptoms related to
DM1 (eg,muscle strength, myotonia, or cataract) occurred after age
40. Otherwise, participants were classified as having the adult form
of DM1, which included the juvenile phenotype at the time of the
study. Individuals with another condition influencing participation
(eg, stroke) were excluded. For the follow-up, individuals were
excluded if they could not give informed consent (eg, developed
dementia) following a screening for potential new health problems
which was carried out by their nurse case manager. The study was
conducted at the neuromuscular clinic and the participant’s home.
Consent was obtained at both assessment times, and the Ethics
Review Board approved the study (#2010-046).Measurements
Data collection procedures, including the questionnaire adminis-
tration sequence and the time of the year (Nordic climate), were
kept as similar as possible for both measurements. To limit
interrater disagreement, the rater of the first measurement trained
the rater of the second measurement. Also, standardized proced-
ures and examples were used. At the neuromuscular clinic, soci-
odemographic and clinical characteristics of participants as well
as disease duration were collected by a research assistant. The
number of CTG repeats was assessed using a standard proced-
ure.34 Overall progression of muscular impairment was measured
using the DM1-specific MIRS based on manual muscle testing and
the presence of myotonia.37 Stages 1-5 indicated no muscular
impairment to severe proximal weakness.37
A number of participation definitions exist, and the tool used to
assess participation must be consistent with them.38 No specific
DM1 participation assessment tools existed at the beginning of the
study.39 Among existing definitions, the HDM-DCP framework
provided a concrete and mutually exclusive definition of the
components related to participation, activities, and capacitieswww.archives-pmr.org
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Fig 1 Participants’ flow chart.
9-year progressive decline in activities 1631compared with other models, such as the International Classifi-
cation of Functioning, Disability and Health.40 Based on the
HDM-DCP framework, the short 3.1 version of the Assessment of
Life Habits questionnaire (LIFE-H) was used to assess participa-
tion.41 Psychometric properties of the LIFE-H 3.1 have been
documented in the DM1 population. It was completed at the
participant’s home and administered by one trained occupationalwww.archives-pmr.orgtherapist at baseline and another at follow-up. This questionnaire
includes 77 items (ie, activities) covering the 12 domains of
participation (number of activities): nutrition (4), fitness (4), per-
sonal care (8), communication (8), housing (8), mobility (5), re-
sponsibilities (8), interpersonal relationships (7), community life
(8), education (2), employment (8), and recreation (7). The first 6
domains refer to participation in daily activities and the last 6 to
1632 K. Raymond et alparticipation in social activities. Scores are provided for each
domain, 2 subscores (daily and social activities), and the total
score (global participation). Because no participant was at school
and only 20 of them were employed, the education and employ-
ment domains were not analyzed, and results are not shown. The
questionnaire considers accomplishment level and satisfaction
level in participation. Accomplishment level is assessed with a 10-
point scale from 9-0, using level of difficulty and assistance
required as participation’s indicators (supplemental table S1,
available online only at http://www.archives-pmr.org/). A change
of 0.5 (/9) is considered a minimal clinically important difference
(MCID).42 Also, a score of 7 indicates a disruption (ie,
accomplished with difficulty), while a score of 5 indicates a
severe disruption (ie, accomplished with human assistance).41
These cutoffs give a clinical comprehension of accomplishment
level in participation. Satisfaction level is assessed with a 5-point
scale from 1-5, with a higher mean score indicating greater
satisfaction (see supplemental table S1). There is no known MCID
for satisfaction change. For DM1, the LIFE-H shows excellent
reliability for domains, subscores, and total score, with intraclass
correlation coefficients (ICCs) ranging from 0.80-0.91 for intra-
rater reliability and 0.86-0.92 for interrater reliability.43 Poor
intrarater and interrater reliability were found for 2 domains:
fitness (ICC, 0.20 and 0.21, respectively) and communication
(ICC, 0.12 and 0.47, respectively). However, these domains
showed excellent agreement according to Bland and Altman
graphs, indicating that this may be because of the homogeneity of
the sample. The LIFE-H showed validity with various
populations.44-46
Data analysis
Descriptive statistics were used to define the participants. To
document selection bias, baseline characteristics of the individuals
who participated at baseline but did not attend follow-up, herein-
after named lost to follow-up, were compared with the baseline
characteristics of participants using the Mann-Whitney test
(continuous variables) or chi-square test (nominal variables). There
were no missing data for participation except for nutrition and
recreation (<5%). With respect to the assumption of sphericity,
repeated measures analysis of variance (RM-ANOVA) was used to
compare follow-up (T2) with baseline (T1) for accomplishment and
satisfaction. Within-participant effects, a subtest of RM-ANOVA,
allowed exploratory comparison of changes in accomplishment for
sex subgroup. To detect clinical changes, a mean difference in
accomplishment (DZT2T1) was calculated and compared with
the MCID. Also, descriptive analyses were used to estimate the
proportion and percentage of participants with decreased (MCID)
or improved (MCID) participation over the 9-year interval. A
comparison with typical aging reference values47 was performed
using Wilcoxon rank-sum test. Reference values were chosen
because they were collected with the same assessment procedure in
the Quebec population, the most similar population to ours. How-
ever, values were only available for adults 55 years or older within a
cross-sectional design. Reference values of the group aged 55-64
years (the closest to the participants’ age) were chosen for com-
parison. The latter was performedwith thewhole DM1 sample as an
exploratory objective, nomatter how old participants were, to better
inform on the participants’ level of participation. It is worth noting
that education and employment domains are also excluded from
these reference values because they are often not applicable for
older adults. Cutoffs were used to determine the proportion ofparticipants with disrupted and severely disrupted participation over
time, while McNemar chi-square test was used to compare changes
over time. As a supplemental descriptive and exploratory analysis,
changes in the activities in each domain were explored with RM-
ANOVA and compared with the MCID. The statistical analyses
were performed using SPSSa software (version 21.0 for Windows),
and aZ0.05 was used.Results
Of the 200 participants at baseline, 115 completed the study 9
years later (fig 1). The participants who completed follow-up did
not differ at baseline from the 85 lost to follow-up in terms of sex,
CTG, and phenotypic distribution. However, compared with par-
ticipants, lost to follow-up were older at baseline (51.612.1 vs
43.610.3 years old; P<.01), had greater disease severity ac-
cording to the MIRS (P<.001), and were more restricted in their
participation at baseline for each domain, subscores, and the total
score (P<.01). The 59 participants who died before the follow-up
did not differ from the 26 who were excluded or refused to
participate in term of sex (PZ.638) but were older (PZ.002) and
presented greater disease severity (P<.001). The 26 participants
excluded or who refused to participate were not different from the
115 participants in terms of sex, age, and disease severity (P>.05).
A total of 62% of participants were women (table 1) aged 29-85
years with a disease duration ranging from 12-47 years. Most
participants were living at home with a spouse or other relatives,
had a family income of less than C$19,999, and were receiving
community services (eg, household assistance, meal delivery).
The housing situation of half of the participants changed during
the study. One person was living in a long-term care facility at
baseline and an additional 3 were at follow-up.
Participation decreased over 9 years for the total score, social
activities subscore, and 6 domains: nutrition, fitness, personal
care, mobility, community life, and recreation (table 2). Recrea-
tion showed the greatest decline (ie, triple the MCID). Based on
standard deviation of delta, individual trajectories of participation
differ. At follow-up, no participants showed a complete disruption
of participation (0/9) except for recreation (6.3%).
Participants reported to be “satisfied” and “very satisfied” at
both measurements for global participation, daily and social ac-
tivities subscores, and all domains (see table 2). Satisfaction was
stable over time for all domains.
Women and men were similar with respect to age and disease
duration (supplemental table S2, available online only at http://www.
archives-pmr.org/). Participation change over 9 years was mostly
similar for both sexes on a statistical point of view. A trend worth
noting was men’s changes in each domain were consistently greater
than women’s. The latter almost improved over time for housing
while men declined. However, men showed a greater clinical decline
(above MCID) than women only for fitness (table 3).
When compared with typical aging adults aged 55-64 years,47
participation as well as daily and social activities were similar to
reference values at baseline but lower at follow-up even though
participants were younger at follow-up (52.310.3y vs
60.43.1y; see table 2). More specifically, fitness, mobility, and
community life were already below reference values at baseline.
In addition to these 3 domains, personal care and recreation were
also below reference values at follow-up.
More than one-third of participants showed a decrease in
participation, daily and social activities, and all domains exceptwww.archives-pmr.org
Table 1 Participants’ characteristics (NZ115)
Characteristics Baseline (T1) Follow-up (T2)
Age (y) 43.610.3 52.310.3






50-200 23 (20.0) 13 (11.3)
201-1000 55 (47.8) 36 (31.3)
>1000 37 (32.2) 64 (55.7)
Missing 2 (1.7)
Disease duration (y) 19.9 (8.1) 28.8 (8.1)
Missing (nZ34, 29.6%)
MIRS
Grade 1 6 (5.2) 1 (0.9)
Grade 2 14 (12.2) 5 (4.3)
Grade 3 27 (23.5) 23 (20.0)
Grade 4 62 (53.9) 66 (57.4)
9-year progressive decline in activities 1633for communication, responsibilities, and interpersonal relation-
ships (see table 2). For housing, a decrease was observed in about
one-third of participants over the 9-year period, while an increase
was observed in approximately another third. For mobility, a
similar pattern to housing was observed.
Compared with baseline, a greater disruption in participation
was found at follow-up, with more than 1 participant of 10
showing a disruption in almost all participation scores (table 4). A
more severe disruption (ie, requiring human assistance) was found
specifically in nutrition, fitness, mobility, community life, and
recreation at follow-up.
Among daily activities, activities with the largest clinical
change in each domain were preparing meals, participating in
physical activities to maintain fitness, putting on an assistive de-
vice and attending to personal hygiene, maintaining the home and
grounds, and riding a bicycle (supplemental table S3, available
online only at http://www.archives-pmr.org/). Among social ac-
tivities, those with the largest clinical change were making pur-
chases, having a sexual relationship, using public services and
neighborhood businesses, taking part in outdoor activities, and
participating in sporting or recreational activities.Grade 5 5 (4.3) 13 (11.3)
Missing 1 (0.9) 7 (6.1)
Family income (Canadian $)
<10,000 20 (17.4) 11 (9.6)
10,000-19,999 38 (33.0) 51 (44.3)
20,000-39,999 20 (17.4) 24 (20.9)
40,000-59,999 10 (8.7) 16 (13.9)
>60,000 18 (15.6) 12 (10.4)
Unknown/refused 9 (7.8) 1 (0.9)
Education level (y)
11 50 (43.5) 50 (43.5)
12-13 49 (42.6) 49 (42.6)
14-16 14 (12.1) 12 (10.4)
17 2 (1.7) 4 (3.5)
Living arrangement
Home alone 19 (16.5) 32 (27.8)
Home with spouse or other(s) 95 (82.6) 79 (68.7)
Long-term care facility 1 (0.9) 4 (3.5)
Residence characteristics
Ground floor 37 (32.2) 72 (62.6)
Basement or upper floors 78 (67.8) 43 (37.4)
Relocation during study 57 (49.6)
Receiving community services
Household assistance 50 (43.5) 56 (48.7)
Adapted transportation 21 (18.3) 26 (22.6)
Meals delivery service 15 (13.0) 8 (7.0)
Home adaptation 16 (13.9) 17 (14.8)
NOTE. Values expressed as mean  SD for continuous variables and
frequency (%) for categorical variables.Discussion
This study is the first to assess participation changes over a 9-year
period in adults with DM1, explore sex discrepancy, and make
comparisons with reference values from a typical aging popula-
tion. Partially confirming the first hypothesis, individuals with
DM1 experienced more restrictions in participation over time but
not all participants nor in all domains. Similar for both sexes, 6
domains of participation (4 daily activities [nutrition, fitness,
personal care, mobility] and 2 social activities [community life
and recreation]) decreased. Clinical improvement and decline
were found almost equally for housing and mobility. Although a
trend for men having higher decline than women was identified,
the second hypothesis was infirmed because almost no clinical
difference for decline was found between women and men. At
follow-up, most scores were below reference values from a typical
aging population aged 55-64 years, partially confirming the third
hypothesis. These results are of importance because they have the
potential to guide long-term intervention targeting participation
and to better inform health care professionals and families about
the disease prognosis.
Participation accomplishment level
A decrease in global participation as well as in social activities for
adults with DM1 was expected. Of the 6 domains that decreased
over 9 years, only 3 were highlighted in previous studies.9,28 This
study was the first to document a decline in nutrition, fitness, and
community life, whereas housing, communication, responsibilities,
and interpersonal relationships were stable. Contrary to the current
findings, Bostrom et al28 reported no change over a 10-year period
in eating (included in nutrition), sleep, and rest (included in fitness)
and a decrease in home maintenance (included in housing) for 25
participants with DM1. However, they28 measured activity limita-
tions (Sickness Impact Profile48), which covers only some items
from the LIFE-H.
Surprisingly, in the current study, a significant proportion of people
showed an improvement for housing and mobility. Because partici-
pation results from the interaction of personal and environmentalwww.archives-pmr.orgfactors,15 better participation over time could be explained by several
factors. For example, adaptation to impairment (eg, a response-shift
implying shifting internal reference system, such as values and
coping with a disease, which has been documented in other progres-
sive disease and during the aging process49,50), care improvement (eg,
over the 9-year period, a home health service was implemented at the
neuromuscular clinic where the study took place), or a change in
physical environment (eg, half of the cohort moved within the 9-year
period, and, of them, 61% moved from basement or upper floor to a
Table 2 Comparison of participation and satisfaction scores at baseline and follow-up (NZ115)
Participation Score (/9) Reference Values* T1 T2 Dy Pz Decreasex Improvementk
Satisfaction Score (/5)
T1 T2 Pz
Participation (total score) 8.40.3 8.30.8{ 7.81.2# 0.510.9** <.001 39 (33.9) 7 (6.1) 4.50.5 4.50.4 .06
Daily activities 8.30.3 8.20.8{ 7.81.2# 0.430.9 <.001 40 (34.8) 8 (7.0) 4.50.5 4.50.4 .14
Nutrition (nZ113) 8.11.3 8.50.8yy 7.81.8{ 0.721.4** <.001 38 (33.6) 5 (4.4) 4.60.5 4.70.4 <.01
Fitness 8.70.5 8.11.2# 7.11.7# 1.001.6** <.001 63 (54.8) 14 (12.2) 4.20.7 4.10.8 .23
Personal care 8.90.1 8.70.6{ 8.01.4# 0.681.2** <.001 43 (37.4) 5 (4.3) 4.60.5 4.70.5 .20
Communication 8.40.5 8.70.5yy 8.61.0yy 0.101.0 .26 19 (16.5) 12 (10.4) 4.60.5 4.60.4 .23
Housing 7.50.9 7.51.5{ 7.41.5{ 0.091.4 .50 36 (31.3) 33 (28.7) 4.40.6 4.50.5 .09
Mobility 8.30.7 7.51.7# 7.02.1# 0.541.9** <.01 50 (43.5) 26 (22.6) 4.30.7 4.30.8 .96
Social activities 8.50.4 8.30.9{ 7.71.4# 0.611.2** <.001 44 (38.3) 8 (7.0) 4.40.5 4.60.5 .03
Responsibilities 8.40.8 8.70.7yy 8.61.0yy 0.160.8 .04 21 (18.3) 10 (8.7) 4.70.4 4.80.4 .07
Interpersonal relationships 8.40.8 8.60.7yy 8.41.0{ 0.231.1 .02 25 (21.7) 12 (10.4) 4.50.5 4.60.5 .04
Community life 8.90.3 8.51.1# 7.72.0# 0.771.9** <.001 41 (35.7) 12 (10.4) 4.50.5 4.60.6 .08
Recreation (nZ111) 8.31.2 7.32.4{ 5.83.0# 1.533.0** <.001 57 (51.4) 15 (13.5) 4.20.9 4.11.0 .43
NOTE. Values expressed as mean  SD for continuous variables and frequency (%) for categorical variables.
* Reference values available for typical people aged 55-64 years.
y Negative value indicated decrease participation score.
z Repeated-measures analysis of variance.
x Proportion of participants (n [%]) whose participation scores have decreased (0.50) over time.
k Proportion of participants (n [%]) whose participation scores have improved (0.50) over time.
{ Similar to reference values with Wilcoxon rank-sum test (not significant).
# Below reference values with Wilcoxon rank-sum test (P<.001).
** Clinical change (minimally clinically important difference [MCID] 0.50).






















Table 3 Comparison participation scores changes from baseline to follow-up in women (nZ72) and men (nZ43)
Participation Score (/9)
Women, Mean  SD Men, Mean  SD
Py
Women, n (%) Men, n (%)
T1 T2 D* T1 T2 D* Decreasez Improvementx Decreasez Improvementx
Participation (total score) 8.20.8 7.91.0 0.370.7 8.30.8 7.51.4 0.751.2k .04 21 (29.2) 7 (9.7) 17 (39.5) 1 (2.3)
Daily activities 8.20.8 7.91.0 0.270.7 8.30.8 7.61.4 0.701.1k .013 21 (29.2) 7 (9.7) 22 (51.2) 1 (2.3)
Nutrition (w: nZ70) 8.50.9 7.91.6 0.601.1k 8.60.8 7.62.1 0.931.7k .21 23 (32.9) 3 (4.3) 15 (34.9) 2 (4.7)
Fitness 8.01.3 7.31.6 0.681.6k 8.21.1 6.61.8 1.551.5k .013 35 (48.6) 13 (18.1) 28 (65.1) 1 (2.3)
Personal care 8.70.5 8.21.2 0.550.9k 8.60.7 7.71.7 0.901.6k .12 26 (36.1) 3 (4.2) 17 (39.5) 2 (4.7)
Communication 8.80.3 8.80.6 0.010.5 8.50.6 8.31.5 0.251.4 .21 9 (12.5) 5 (6.9) 10 (23.3) 7 (16.3)
Housing 7.41.5 7.51.5 0.111.5 7.81.4 7.31.5 0.421.1 .042 19 (26.4) 25 (34.7) 17 (39.5) 8 (18.6)
Mobility 7.41.8 7.02.1 0.412.0 7.71.6 7.02.0 0.751.7k .44 27 (37.5) 19 (26.4) 23 (53.5) 7 (16.3)
Social activities 8.30.9 7.81.2 0.501.0k 8.30.9 7.51.5 0.811.5k .19 28 (38.9) 7 (9.7) 18 (41.9) 6 (14.0)
Responsibilities 8.70.6 8.70.9 0.060.6 8.70.8 8.41.3 0.331.1 .08 10 (13.9) 6 (8.3) 11 (25.6) 4 (9.3)
Interpersonal relationships 8.60.7 8.50.8 0.070.9 8.70.8 8.21.2 0.501.2k .036 12 (16.7) 10 (13.9) 13 (30.2) 2 (4.7)
Community life 8.41.2 7.82.0 0.621.9k 8.60.9 7.62.2 1.022.0k .28 24 (33.3) 11 (15.3) 17 (39.5) 1 (2.3)
Recreation (w: nZ70, m: nZ41) 7.42.5 6.03.0 1.342.8k 7.22.6 5.53.0 1.873.2k .36 34 (48.6) 11 (15.7) 24 (58.5) 5 (12.2)
Abbreviations: m, men; w, women.
* Negative value indicated decrease participation score.
y Repeated-measures analysis of variance, test of within-participant effects for sex.
z Proportion of participants whose participation scores have decreased (0.50) over time.
x Proportion of participants whose participation scores have improved (0.50) over time.
























Table 4 Comparison of participants experiencing disruption at baseline and follow-up (NZ115)
Disruption, n (%) (Cutoff: 7) Severe Disruption, n (%) (Cutoff: 5)
T1 T2 T1 T2
Participation (total score) 11 (9.6) 23 (20.0)* 0 (0.0) 5 (4.3)
Daily activities 12 (10.4) 23 (20.0)* 0 (0.0) 3 (2.6)*
Nutrition (nZ113) 10 (8.8) 30 (26.5)* 1 (0.9) 17 (15.0)*
Fitness 21 (18.3) 53 (46.1)* 6 (5.2) 19 (16.5)*
Personal care 1 (0.9) 17 (14.8)* 0 (0.0) 8 (7.0)*
Communication 3 (2.6) 6 (5.2) 0 (0.0) 3 (2.6)
Housing 46 (40.0) 44 (38.3) 5 (4.3) 8 (7.0)
Mobility 37 (32.2) 51 (44.3)* 14 (12.2) 19 (16.5)
Social activities 13 (11.3) 31 (27.0)* 1 (0.9) 7 (6.1)
Responsibilities 5 (4.3) 10 (8.7) 0 (0.0) 2 (1.7)
Interpersonal relationships 5 (4.3) 10 (8.7) 0 (0.0) 1 (0.9)
Community life 10 (8.7) 24 (20.9)* 3 (2.6) 15 (13.0)*
Recreation (nZ111) 39 (35.1) 64 (57.7)* 18 (16.2) 41 (36.9)*
* McNemar c2 test (P<.05).
1636 K. Raymond et alground floor residence) may have contributed to participation
improvement. Nevertheless, as the disease progressed, disruption in
participation increased and new activities were disrupted over time,
highlighting several considerations for medical, rehabilitation, and
community services.
Comparison with a typical aging population
People of various ages with DM1 showed a lower accomplishment
level on the majority of participation domains compared with a
cohort of typical aging adults aged 55-64 years,47 even though
they were younger at follow-up. This suggests that adults with
DM1 showed not only age-related changes in participation but
faced disease-specific restrictions.
Otherwise, in the current study, men showed a clinically higher
decrease than women only in fitness, but this trend can be found
for almost all domains. In a typical aging population, a sex dif-
ference in participation accomplishment level was identified in
only 4 domains, in other words, women showed higher partici-
pation in nutrition and interpersonal relationships and lower
participation in housing and mobility than men.47 No sex differ-
ence was found for the other domains, subscores, and global
participation in the typical aging population.
Participation satisfaction level
Although several domains were disrupted and decreased over 9
years, satisfaction with participation was high and stable. Because
greater quality of life over time had been already reported in the
DM1 population,51,52 it is not completely surprising to observe
stability in satisfaction level. In fact, quality of life has been more
associated with satisfaction than with accomplishment for the
aging population.49 Several factors could explain high and stable
satisfaction, such as adaptation to the disease9-11,28 with coping
strategies53 and response shift.54
Furthermore, emotional functioning has been reported as a
predictor of satisfaction with participation.24 Apathy55 and lack of
disease awareness56 could also interfere with self-assessment of
satisfaction. More studies should explore these hypotheses.
Nevertheless, even if high satisfaction is reported by individualswith DM1, disrupted participation continues to be an important
outcome of rehabilitation success because it places a heavy burden
on individuals, their social network, and society.
Clinical implications
A decrease in participation domains that were usually not re-
ported to be disrupted or at risk of a decrease over time could
lead to unmet needs in interventions and services related to long-
term maintenance of participation. Based on a previous study,11
a disruption in at least 10% of the sample is considered of
importance for clinical care. Indeed, identification of specific
disrupted activities over time might guide rehabilitation pro-
fessionals’ interventions. For example, as cognitive behavioral
therapy with graded exercises suggested improvement in
participation for the DM1 population,57 targeting specific ac-
tivities could provide more concrete anchorage in a person’s life
to guide therapy. In fact, cognitive orientation to daily occupa-
tional performance targeting specific activities showed partici-
pation improvement in various populations58,59 and could be a
promising avenue in the DM1 population. Because more people
with DM1 had more difficulty or required human assistance over
time, there is a need for health care or community services to be
provided at the right time. Because interventions targeting
participation must be personalized to implement evidence-based
practice,60 health professionals might monitor specific activities
with a greater decrease over time for each domain of
participation.
Study limitations
To our knowledge, this is the first study using a descriptive lon-
gitudinal design with a large cohort to assess participation in
DM1. However, with respect to limitations, because the majority
of nonparticipants died over the 9-year period,61 were older, and
had greater disease severity, the study’s first limitation was a
survival bias. Although this phenomenon was similar in a previous
DM1 study,28 results presented here might give a better portrait of
participation in DM1. Second, generalization to younger people
with DM1 may be jeopardized. Participants’ disease duration waswww.archives-pmr.org
9-year progressive decline in activities 1637around 30 years, and their adaptation to the disease as well as their
accomplishment level may be different from that of people with
shorter disease duration. In addition, because disease duration was
different for each participant, with no basal common time, the
decline trajectory could not be interpreted as linear. Third, people
with DM1 are known for their diminished disease awareness,56
which might influence their capacity to self-evaluate their
participation with a questionnaire such as the LIFE-H, especially
for less concrete domains (eg, interpersonal relationships). Fourth,
given its scoring system (eg, with difficulty or no difficulty), the
LIFE-H 3.1 might not detect subtle changes in difficulty level for
accomplishment compared with the LIFE-H 4.0, which shaded the
level of difficulty. The 2 last limits might lead to potential unde-
tected changes over time. Also, because education and employ-
ment domains were not shown, the participation portrait remains
incomplete. Fifth, the comparison with typical aging is explor-
atory and should be carefully interpreted considering that refer-
ence values were extracted from a cross-sectional study, for a
specific age subgroup, and not from a control group. Considering
the sample size, comparison was made with the whole sample and
not with the subsample of the same specific age subgroup leading
to potential bias. Sixth, societal changes affecting participation
(eg, development of technology, changes in government policies)
may have occurred since the end of the data collection. Despite the
time passed since the end of data collection, we think results
provide crucial information to guide interdisciplinary management
of DM1 and may still improve prognosis given to family. Finally,
this study only involved 2 measurements that do not inform about
changes that could happen between measurement times and did
not provide information about participation of people lost to
follow-up. Although sex discrepancy was explored, gender (ie, a
person’s self-identity) was not recorded, leading to an unknown
potential discrepancy for participation change according
to gender.Conclusion
New disrupted participation domains were found over the 9-year
interval for adults with DM1. Housing, mobility, employment, and
recreation were already known to be disrupted,11 but a decrease
over time was found in global participation, social activities, and
more specifically in nutrition, fitness, personal care, mobility,
community life, and recreation. Because housing and mobility
might be more influenced by environmental factors, both
improvement and decline were found. Further investigations are
needed to determine the personal and environmental factors
influencing changes in participation to identify potential in-
terventions or services that could maintain or improve it. Future
studies should include >2 measurement times, make comparisons
according to phenotype, and consider changes in education and
employment domains given their importance for adulthood life.
Also, longitudinal studies conducted on participation restrictions
in the DM1 population using complementary disease-specific
evaluation methods (ie, DM1-Activ or Individualized Neuromus-
cular Quality of Life Questionnaire) should be undertaken as well
as comparison with general population controls. A description of
participation changes may allow health care professionals to
improve health services planning and the everyday life activities
of individuals living with DM1.www.archives-pmr.orgSupplier
a. SPSS version 21.0; IBM.Keywords
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